Race Oncology Ltd. (AU:RAC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Race Oncology Ltd successfully held its Annual General Meeting with all resolutions carried on a poll. The company’s focus remains on advancing its lead asset, bisantrene, in the fight against cancer, offering a promising therapeutic with reduced cardiotoxicity and significant potential in oncology treatment. Investors may find Race’s strategic collaborations and pursuit of commercial opportunities noteworthy as they aim to expand bisantrene’s reach globally.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.